144 related articles for article (PubMed ID: 38672257)
1. The Role of Pretreatment Serum Interleukin 6 in Predicting Short-Term Mortality in Patients with Advanced Pancreatic Cancer.
Park SJ; Park JY; Shin K; Hong TH; Kim Y; Kim IH; Lee M
Biomedicines; 2024 Apr; 12(4):. PubMed ID: 38672257
[TBL] [Abstract][Full Text] [Related]
2. Serum biomarker panel diagnostics in pancreatic ductal adenocarcinoma: the clinical utility of soluble interleukins, IFN-γ, TNF-α and PD-1/PD-L1 in comparison to established serum tumor markers.
Dorman K; Gerckens M; Kruger S; Krueger K; Mayer Z; Rupp A; Zhang D; Weiss L; Westphalen CB; Haas M; Guenther M; Ormanns S; Klawonn F; Werner J; von Bergwelt-Baildon M; Heinemann V; Boeck S; Holdenrieder S
J Cancer Res Clin Oncol; 2023 Jun; 149(6):2463-2474. PubMed ID: 35737090
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of elevated serum soluble CD40 ligand levels as a diagnostic and prognostic tumor marker for pancreatic ductal adenocarcinoma.
Chung HW; Lim JB
J Transl Med; 2014 Apr; 12():102. PubMed ID: 24745825
[TBL] [Abstract][Full Text] [Related]
4. Preoperative neutrophil-to-lymphocyte ratio as a prognosticator in early stage pancreatic ductal adenocarcinoma.
Abe T; Amano H; Kobayashi T; Hanada K; Nakahara M; Ohdan H; Noriyuki T
Eur J Surg Oncol; 2018 Oct; 44(10):1573-1579. PubMed ID: 29807728
[TBL] [Abstract][Full Text] [Related]
5. Serum fibrinogen as a diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma.
Chung KH; Lee JC; Lee J; Cho IK; Kim J; Jang W; Yoo BC; Hwang JH
Pancreatology; 2020 Oct; 20(7):1465-1471. PubMed ID: 32873483
[TBL] [Abstract][Full Text] [Related]
6. Activation of the IL-6R/Jak/stat pathway is associated with a poor outcome in resected pancreatic ductal adenocarcinoma.
Denley SM; Jamieson NB; McCall P; Oien KA; Morton JP; Carter CR; Edwards J; McKay CJ
J Gastrointest Surg; 2013 May; 17(5):887-98. PubMed ID: 23435739
[TBL] [Abstract][Full Text] [Related]
7. Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study.
Dong Q; Yang XH; Zhang Y; Jing W; Zheng LQ; Liu YP; Qu XJ
World J Surg Oncol; 2014 Jun; 12():171. PubMed ID: 24890327
[TBL] [Abstract][Full Text] [Related]
8. The systemic inflammation response index predicts survival and recurrence in patients with resectable pancreatic ductal adenocarcinoma.
Li S; Xu H; Wang W; Gao H; Li H; Zhang S; Xu J; Zhang W; Xu S; Li T; Ni Q; Yu X; Wu C; Liu L
Cancer Manag Res; 2019; 11():3327-3337. PubMed ID: 31114368
[No Abstract] [Full Text] [Related]
9. Markers of tumor inflammation as prognostic factors for overall survival in patients with advanced pancreatic cancer receiving first-line FOLFIRINOX chemotherapy.
Kamposioras K; Papaxoinis G; Dawood M; Appleyard J; Collinson F; Lamarca A; Ahmad U; Hubner RA; Wright F; Pihlak R; Damyanova I; Razzaq B; Valle JW; McNamara MG; Anthoney A
Acta Oncol; 2022 May; 61(5):583-590. PubMed ID: 35392758
[TBL] [Abstract][Full Text] [Related]
10. IL-8-Positive Tumor-Infiltrating Inflammatory Cells Are a Novel Prognostic Marker in Pancreatic Ductal Adenocarcinoma Patients.
Fang Y; Saiyin H; Zhao X; Wu Y; Han X; Lou W
Pancreas; 2016; 45(5):671-8. PubMed ID: 26495785
[TBL] [Abstract][Full Text] [Related]
11. Albumin-to-alkaline phosphatase ratio serves as a prognostic indicator in unresectable pancreatic ductal adenocarcinoma: a propensity score matching analysis.
Zhang K; Dong S; Jing YH; Gao HF; Chen LY; Hua YQ; Chen H; Chen Z
BMC Cancer; 2020 Jun; 20(1):541. PubMed ID: 32517802
[TBL] [Abstract][Full Text] [Related]
12. High methylation levels of PCDH10 predict poor prognosis in patients with pancreatic ductal adenocarcinoma.
Curia MC; Fantini F; Lattanzio R; Tavano F; Di Mola F; Piantelli M; Battista P; Di Sebastiano P; Cama A
BMC Cancer; 2019 May; 19(1):452. PubMed ID: 31088413
[TBL] [Abstract][Full Text] [Related]
13. Pre-treatment serum vitamin D deficiency is associated with increased inflammatory biomarkers and short overall survival in patients with pancreatic cancer.
Rasmussen LS; Yilmaz MK; Falkmer UG; Poulsen LØ; Bøgsted M; Christensen HS; Bojesen SE; Jensen BV; Chen IM; Johansen AZ; Hansen CP; Hasselby JP; Holländer N; Nielsen SE; Andersen F; Bjerregaard JK; Pfeiffer P; Johansen JS
Eur J Cancer; 2021 Feb; 144():72-80. PubMed ID: 33341448
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Serum Interleukin-17 (IL-17) Levels as a Diagnostic Marker in Pancreatic Adenocarcinoma.
Karabulut S; Afsar ÇU; Karabulut M; Alış H; Kılıc L; Çikot M; Yasasever CT; Aykan NF
J Gastrointest Cancer; 2016 Mar; 47(1):47-54. PubMed ID: 26637231
[TBL] [Abstract][Full Text] [Related]
15. Pretreatment platelet to lymphocyte ratio is predictive of overall survival in metastatic pancreatic ductal adenocarcinoma.
Li W; Chen Y; Wang X; Shi Y; Dai G; Li X
Transl Cancer Res; 2019 Feb; 8(1):17-22. PubMed ID: 35116729
[TBL] [Abstract][Full Text] [Related]
16. Impact of Preoperative Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratios on Long-Term Survival in Patients with Operable Pancreatic Ductal Adenocarcinoma.
Romano L; Giuliani A; Tomarelli C; Nervini A; Lazzarin G; Pessia B; Vicentini V; Carlei F; Schietroma M
Med Princ Pract; 2022; 31(6):586-594. PubMed ID: 36323225
[TBL] [Abstract][Full Text] [Related]
17. Validation of IL-7R as an Immunological Biomarker for Human Pancreatic Ductal Adenocarcinoma.
Jang SI; Cho JH; Kim SY; Hong IY; Park JS; Lee HS; Park G; Kim JK; Lee HK; Lee DK
Cancers (Basel); 2022 Feb; 14(3):. PubMed ID: 35159120
[TBL] [Abstract][Full Text] [Related]
18. High level of soluble interleukin-2 receptor in serum predicts treatment resistance and poor progression-free survival in multiple myeloma.
Wang L; Wang JH; Liu WJ; Wang WD; Wang H; Chen XQ; Geng QR; Lu Y; Xia ZJ
Ann Hematol; 2017 Dec; 96(12):2079-2088. PubMed ID: 28871325
[TBL] [Abstract][Full Text] [Related]
19. Systemic immune-inflammation index: a prognostic tiebreaker among all in advanced pancreatic cancer.
Bittoni A; Pecci F; Mentrasti G; Crocetti S; Lupi A; Lanese A; Pellei C; Ciotti C; Cantini L; Giampieri R; Lenci E; Giglio E; Bini F; Copparoni C; Meletani T; Baleani MG; Berardi R
Ann Transl Med; 2021 Feb; 9(3):251. PubMed ID: 33708878
[TBL] [Abstract][Full Text] [Related]
20. GREM1 is a novel serum diagnostic marker and potential therapeutic target for pancreatic ductal adenocarcinoma.
Yang S; Zhang Y; Hua Y; Cui M; Wang M; Gao J; Liu Q; Liao Q
Front Oncol; 2022; 12():968610. PubMed ID: 36091126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]